Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Clinical Trial of TQB2922 Injection (Subcutaneous Administration) Combined With Chemotherapy as First-Line Treatment for RAS/BRAF Wild-Type Unresectable Metastatic Colorectal Cancer

NCT07844187 is registered in ClinicalTrials.gov with Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT07844187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Clinical Trial of TQB2922 Injection (Subcutaneous Administration) Combined With Chemotherapy as First-Line Treatment for RAS/BRAF Wild-Type Unresectable Metastatic Colorectal Cancer
Lead sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 20, 2026
Completion date
March 31, 2028
Enrollment
64 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms